References:
Ahmed, A. U., Auffinger, B., & Lesniak, M. S. (2013). Understanding glioma stem cells: rationale, clinical relevance and therapeutic strategies. Expert Review of Neurotherapeutics , 13 (5), 545-555. https://doi.org/10.1586/ern.13.42
Allen, M., Bjerke, M., Edlund, H., Nelander, S., & Westermark, B. (2016). Origin of the U87MG glioma cell line: Good news and bad news.Science Translational Medicine , 8 (354), 354re353-354re353. https://doi.org/10.1126/scitranslmed.aaf6853
Auffinger, B., Spencer, D., Pytel, P., Ahmed, A. U., & Lesniak, M. S. (2015). The role of glioma stem cells in chemotherapy resistance and glioblastoma multiforme recurrence. Expert Rev Neurother ,15 (7), 741-752. https://doi.org/10.1586/14737175.2015.1051968
Binabaj, M. M., Bahrami, A., ShahidSales, S., Joodi, M., Joudi Mashhad, M., Hassanian, S. M., Anvari, K., & Avan, A. (2018). The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials. J Cell Physiol , 233 (1), 378-386. https://doi.org/10.1002/jcp.25896
Costa, E. C., Moreira, A. F., de Melo-Diogo, D., Gaspar, V. M., Carvalho, M. P., & Correia, I. J. (2016). 3D tumor spheroids: an overview on the tools and techniques used for their analysis.Biotechnol Adv , 34 (8), 1427-1441. https://doi.org/10.1016/j.biotechadv.2016.11.002
Devarasetty, M., Dominijanni, A., Herberg, S., Shelkey, E., Skardal, A., & Soker, S. (2020). Simulating the human colorectal cancer microenvironment in 3D tumor-stroma co-cultures in vitro and in vivo.Sci Rep , 10 (1), 9832. https://doi.org/10.1038/s41598-020-66785-1
Di Cristofano, A., Kotsi, P., Peng, Y. F., Cordon-Cardo, C., Elkon, K. B., & Pandolfi, P. P. (1999). Impaired Fas response and autoimmunity in Pten+/- mice. Science , 285 (5436), 2122-2125. https://doi.org/10.1126/science.285.5436.2122
Dominijanni, A. J., Devarasetty, M., Forsythe, S. D., Votanopoulos, K. I., & Soker, S. (2021). Cell Viability Assays in Three-Dimensional Hydrogels: A Comparative Study of Accuracy. Tissue Engineering Part C: Methods , 27 (7), 401-410. https://doi.org/10.1089/ten.tec.2021.0060
Donson, A. M., Addo-Yobo, S. O., Handler, M. H., Gore, L., & Foreman, N. K. (2007). MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma. Pediatr Blood Cancer , 48 (4), 403-407. https://doi.org/10.1002/pbc.20803
Fedele, M., Cerchia, L., Pegoraro, S., Sgarra, R., & Manfioletti, G. (2019). Proneural-Mesenchymal Transition: Phenotypic Plasticity to Acquire Multitherapy Resistance in Glioblastoma. Int J Mol Sci ,20 (11). https://doi.org/10.3390/ijms20112746
Forsythe, S., Mehta, N., Devarasetty, M., Sivakumar, H., Gmeiner, W., Soker, S., Votanopoulos, K., & Skardal, A. (2019). Development of a Colorectal Cancer 3D Micro-tumor Construct Platform From Cell Lines and Patient Tumor Biospecimens for Standard-of-Care and Experimental Drug Screening. Ann Biomed Eng . https://doi.org/10.1007/s10439-019-02269-2
Frantz, C., Stewart, K. M., & Weaver, V. M. (2010). The extracellular matrix at a glance. Journal of Cell Science , 123 (24), 4195-4200. https://doi.org/10.1242/jcs.023820
Fusenig, N. E., Capes-Davis, A., Bianchini, F., Sundell, S., & Lichter, P. (2017). The need for a worldwide consensus for cell line authentication: Experience implementing a mandatory requirement at the International Journal of Cancer. PLOS Biology , 15 (4), e2001438. https://doi.org/10.1371/journal.pbio.2001438
Gielen, P. R., Aftab, Q., Ma, N., Chen, V. C., Hong, X., Lozinsky, S., Naus, C. C., & Sin, W. C. (2013). Connexin43 confers Temozolomide resistance in human glioma cells by modulating the mitochondrial apoptosis pathway. Neuropharmacology , 75 , 539-548. https://doi.org/10.1016/j.neuropharm.2013.05.002
Grek, C. L., Sheng, Z., Naus, C. C., Sin, W. C., Gourdie, R. G., & Ghatnekar, G. G. (2018). Novel approach to temozolomide resistance in malignant glioma: connexin43-directed therapeutics. Curr Opin Pharmacol , 41 , 79-88. https://doi.org/10.1016/j.coph.2018.05.002
Heimberger, A. B., Crotty, L. E., Archer, G. E., Hess, K. R., Wikstrand, C. J., Friedman, A. H., Friedman, H. S., Bigner, D. D., & Sampson, J. H. (2003). Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res , 9 (11), 4247-4254. https://www.ncbi.nlm.nih.gov/pubmed/14519652
Hoarau-Véchot, J., Rafii, A., Touboul, C., & Pasquier, J. (2018). Halfway between 2D and Animal Models: Are 3D Cultures the Ideal Tool to Study Cancer-Microenvironment Interactions? Int J Mol Sci ,19 (1). https://doi.org/10.3390/ijms19010181
Jiang, J., Hoagland, D., Palatinus, J. A., He, H., Iyyathurai, J., Jourdan, L. J., Bultynck, G., Wang, Z., Zhang, Z., Schey, K., Poelzing, S., McGowan, F. X., & Gourdie, R. G. (2019). Interaction of α Carboxyl Terminus 1 Peptide With the Connexin 43 Carboxyl Terminus Preserves Left Ventricular Function After Ischemia‐Reperfusion Injury. Journal of the American Heart Association , 8 (16), e012385. https://doi.org/10.1161/JAHA.119.012385
Lee, S. Y. (2016). Temozolomide resistance in glioblastoma multiforme.Genes Dis , 3 (3), 198-210. https://doi.org/10.1016/j.gendis.2016.04.007
Malkki, H. (2016). Trial Watch: Glioblastoma vaccine therapy disappointment in Phase III trial. Nat Rev Neurol , 12 (4), 190. https://doi.org/10.1038/nrneurol.2016.38
Maloney, E., Clark, C., Sivakumar, H., Yoo, K., Aleman, J., Rajan, S. A. P., Forsythe, S., Mazzocchi, A., Laxton, A. W., Tatter, S. B., Strowd, R. E., Votanopoulos, K. I., & Skardal, A. (2020). Immersion Bioprinting of Tumor Organoids in Multi-Well Plates for Increasing Chemotherapy Screening Throughput. Micromachines (Basel) , 11 (2). https://doi.org/10.3390/mi11020208
Mazzocchi, A., Devarasetty, M., Herberg, S., Petty, W. J., Marini, F., Miller, L., Kucera, G., Dukes, D. K., Ruiz, J., Skardal, A., & Soker, S. (2019). Pleural Effusion Aspirate for use in 3D Lung Cancer Modeling and Chemotherapy Screening. ACS Biomater Sci Eng , 5 (4), 1937-1943. https://doi.org/10.1021/acsbiomaterials.8b01356
Mazzocchi, A. R., Rajan, S. A. P., Votanopoulos, K. I., Hall, A. R., & Skardal, A. (2018). In vitro patient-derived 3D mesothelioma tumor organoids facilitate patient-centric therapeutic screening. Sci Rep , 8 (1), 2886. https://doi.org/10.1038/s41598-018-21200-8
Montgomery, J., Richardson, W. J., Marsh, S., Rhett, J. M., Bustos, F., Degen, K., Ghatnekar, G. S., Grek, C. L., Jourdan, L. J., Holmes, J. W., & Gourdie, R. G. (2021). The connexin 43 carboxyl terminal mimetic peptide αCT1 prompts differentiation of a collagen scar matrix in humans resembling unwounded skin. Faseb j , 35 (8), e21762. https://doi.org/10.1096/fj.202001881R
Munoz, J. L., Rodriguez-Cruz, V., Greco, S. J., Ramkissoon, S. H., Ligon, K. L., & Rameshwar, P. (2014). Temozolomide resistance in glioblastoma cells occurs partly through epidermal growth factor receptor-mediated induction of connexin 43. Cell Death & Disease , 5 (3), e1145-e1145. https://doi.org/10.1038/cddis.2014.111
Murphy, S. F., Varghese, R. T., Lamouille, S., Guo, S., Pridham, K. J., Kanabur, P., Osimani, A. M., Sharma, S., Jourdan, J., Rodgers, C. M., Simonds, G. R., Gourdie, R. G., & Sheng, Z. (2016). Connexin 43 Inhibition Sensitizes Chemoresistant Glioblastoma Cells to Temozolomide.Cancer Res , 76 (1), 139-149. https://doi.org/10.1158/0008-5472.CAN-15-1286
Pridham, K. J., Shah, F., Hutchings, K. R., Sheng, K. L., Guo, S., Liu, M., Kanabur, P., Lamouille, S., Lewis, G., Morales, M., Jourdan, J., Grek, C. L., Ghatnekar, G. G., Varghese, R., Kelly, D. F., Gourdie, R. G., & Sheng, Z. (2022). Connexin 43 confers chemoresistance through activating PI3K. Oncogenesis , 11 (1), 2. https://doi.org/10.1038/s41389-022-00378-7
Roberts, R., Smyth, J. W., Will, J., Roberts, P., Grek, C. L., Ghatnekar, G. S., Sheng, Z., Gourdie, R. G., Lamouille, S., & Foster, E. J. (2020). Development of PLGA nanoparticles for sustained release of a connexin43 mimetic peptide to target glioblastoma cells. Mater Sci Eng C Mater Biol Appl , 108 , 110191. https://doi.org/10.1016/j.msec.2019.110191
Rubenstein, J. L., Li, J., Chen, L., Advani, R., Drappatz, J., Gerstner, E., Batchelor, T., Krouwer, H., Hwang, J., Auerback, G., Kadoch, C., Lowell, C., Munster, P., Cha, S., Shuman, M. A., & Damon, L. E. (2013). Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma. Blood , 121 (5), 745-751. https://doi.org/10.1182/blood-2012-07-440974
Rybinski, B., & Yun, K. (2016). Addressing intra-tumoral heterogeneity and therapy resistance. Oncotarget , 7 (44), 72322-72342. https://doi.org/10.18632/oncotarget.11875
Segerman, A., Niklasson, M., Haglund, C., Bergstrom, T., Jarvius, M., Xie, Y., Westermark, A., Sonmez, D., Hermansson, A., Kastemar, M., Naimaie-Ali, Z., Nyberg, F., Berglund, M., Sundstrom, M., Hesselager, G., Uhrbom, L., Gustafsson, M., Larsson, R., Fryknas, M., . . . Westermark, B. (2016). Clonal Variation in Drug and Radiation Response among Glioma-Initiating Cells Is Linked to Proneural-Mesenchymal Transition. Cell Rep , 17 (11), 2994-3009. https://doi.org/10.1016/j.celrep.2016.11.056
Shen, X., Wu, S., Zhang, J., Li, M., Xu, F., Wang, A., Lei, Y., & Zhu, G. (2020). Wild‑type IDH1 affects cell migration by modulating the PI3K/AKT/mTOR pathway in primary glioblastoma cells. Mol Med Rep ,22 (3), 1949-1957. https://doi.org/10.3892/mmr.2020.11250
Simsa, R., Rothenbücher, T., Gürbüz, H., Ghosheh, N., Emneus, J., Jenndahl, L., Kaplan, D. L., Bergh, N., Serrano, A. M., & Fogelstrand, P. (2021). Brain organoid formation on decellularized porcine brain ECM hydrogels. PLoS ONE , 16 (1), e0245685. https://doi.org/10.1371/journal.pone.0245685
Sivakumar, H., Devarasetty, M., Kram, D. E., Strowd, R. E., & Skardal, A. (2020). Multi-Cell Type Glioblastoma Tumor Spheroids for Evaluating Sub-Population-Specific Drug Response. Frontiers in bioengineering and biotechnology , 8 , 538663-538663. https://doi.org/10.3389/fbioe.2020.538663
Sivakumar, H., Strowd, R., & Skardal, A. (2017). Exploration of Dynamic Elastic Modulus Changes on Glioblastoma Cell Populations with Aberrant EGFR Expression as a Potential Therapeutic Intervention Using a Tunable Hyaluronic Acid Hydrogel Platform. Gels , 3 (3). https://doi.org/10.3390/gels3030028
Sottoriva, A., Spiteri, I., Piccirillo, S. G., Touloumis, A., Collins, V. P., Marioni, J. C., Curtis, C., Watts, C., & Tavare, S. (2013). Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci U S A , 110 (10), 4009-4014. https://doi.org/10.1073/pnas.1219747110
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., Curschmann, J., Janzer, R. C., Ludwin, S. K., Gorlia, T., Allgeier, A., Lacombe, D., Cairncross, J. G., Eisenhauer, E., Mirimanoff, R. O., . . . National Cancer Institute of Canada Clinical Trials, G. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med , 352 (10), 987-996. https://doi.org/10.1056/NEJMoa043330
Swartz, A. M., Li, Q. J., & Sampson, J. H. (2014). Rindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme. Immunotherapy , 6 (6), 679-690. https://doi.org/10.2217/imt.14.21
Taal, W., Oosterkamp, H. M., Walenkamp, A. M., Dubbink, H. J., Beerepoot, L. V., Hanse, M. C., Buter, J., Honkoop, A. H., Boerman, D., de Vos, F. Y., Dinjens, W. N., Enting, R. H., Taphoorn, M. J., van den Berkmortel, F. W., Jansen, R. L., Brandsma, D., Bromberg, J. E., van Heuvel, I., Vernhout, R. M., . . . van den Bent, M. J. (2014). Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol , 15 (9), 943-953. https://doi.org/10.1016/S1470-2045(14)70314-6
Tang, C., Guo, J., Chen, H., Yao, C. J., Zhuang, D. X., Wang, Y., Tang, W. J., Ren, G., Yao, Y., Wu, J. S., Mao, Y., & Zhou, L. F. (2015). Gene mutation profiling of primary glioblastoma through multiple tumor biopsy guided by 1H-magnetic resonance spectroscopy. Int J Clin Exp Pathol , 8 (5), 5327-5335. https://www.ncbi.nlm.nih.gov/pubmed/26191234
Verhaak, R. G., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., Alexe, G., Lawrence, M., O’Kelly, M., Tamayo, P., Weir, B. A., Gabriel, S., Winckler, W., Gupta, S., Jakkula, L., . . . Cancer Genome Atlas Research, N. (2010). Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell , 17 (1), 98-110. https://doi.org/10.1016/j.ccr.2009.12.020
Votanopoulos, K. I., Forsythe, S., Sivakumar, H., Mazzocchi, A., Aleman, J., Miller, L., Levine, E., Triozzi, P., & Skardal, A. (2019). Model of Patient-Specific Immune-Enhanced Organoids for Immunotherapy Screening: Feasibility Study. Ann Surg Oncol . https://doi.org/10.1245/s10434-019-08143-8
Votanopoulos, K. I., Mazzocchi, A., Sivakumar, H., Forsythe, S., Aleman, J., Levine, E. A., & Skardal, A. (2019). Appendiceal Cancer Patient-Specific Tumor Organoid Model for Predicting Chemotherapy Efficacy Prior to Initiation of Treatment: A Feasibility Study.Ann Surg Oncol , 26 (1), 139-147. https://doi.org/10.1245/s10434-018-7008-2
Votanopoulos, K. I., & Skardal, A. (2020). ASO Author Reflections: Co-cultured Lymph Node and Tumor Organoids as a Platform for the Creation of Adaptive Immunity and Predict Response to Immunotherapy.Ann Surg Oncol . https://doi.org/10.1245/s10434-020-08351-7
Zhang, J., Stevens, M. F., & Bradshaw, T. D. (2012). Temozolomide: mechanisms of action, repair and resistance. Curr Mol Pharmacol ,5 (1), 102-114. https://doi.org/10.2174/1874467211205010102